ScholarWorks@Korea University College of Medicine: Oh, Sang Cheul

Detailed Information

Oh, Sang Cheul (오상철)

Guro Hospital (Department of Medical Oncology and Hematology, Guro Hospital)

Research Area

Tel
Homepage

ResearcherID ORCiD Scopus Google Scholar ID ResearchGate

Keyword

Gastric cancer:16||colorectal cancer:7||chemotherapy:7||gastric cancer:7||Oxaliplatin:5||Invasion:5||Prognosis:5||Stomach neoplasms:5||Chemotherapy:5||Colon cancer:4||Gemcitabine:4||Nivolumab:4||Neoplasm metastasis:4||cisplatin:4||Gastroesophageal junction cancer:3||epirubicin:3||apoptosis:3||endoplasmic reticulum stress:3||colon cancer:3||Stomach neoplasm:3||Genipin:3||reactive oxygen species:2||Metastasis:2||reactive oxygen species modulator1:2||angiogenesis:2||hypoxia:2||Ramucirumab:2||Survival:2||Survivin:2||Colorectal cancer:2||Akt:2||stemness:2||stomach neoplasms:2||Hedgehog pathway:2||Rituximab chemotherapy:2||TRAIL:2||leucovorin:2||tumor necrosis factorrelated apoptosisinducing ligand:2||cancer:2||Colorectal neoplasms:2||Migration:2||ER stress:2||vaccine:2||cannabidiol:2||mTOR:2||Gastroesophageal junction:2||Death receptor 5:2||Pancreatic cancer:2||Pancreatic neoplasms:2||위암:2||mitochondrial dysfunction:2||capecitabine:2||colorectal neoplasms:2||Cauda equina syndrome:2||nonsmall cell lung carcinoma:2||Advanced gastric cancer:2||p53:2||UFT:2||UFTE:2||FOLFIRI:2||Neoadjuvant chemotherapy:2||Docetaxel:2||Primary adrenal lymphoma:2||Adjuvant chemotherapy:2||JNK:2||Kidney:2||Quality of life:2||Apoptosis:2||Mcl1:2||Noxa:2||adjuvant:2||ramucirumab:2||DNA damage:1||DUKESB:1||Death receptor 5 (DR5):1||Diallyl disulphide:1||Distribution:1||Drug therapy:1||EMT:1||EORTC QLQC30:1||EPHB3:1||EPITHELIALCELLS:1||EQ5D:1||ERK:1||ERK phosphorylation:1||Early progression:1||Elderly:1||Enzymelinked immunosorbent assay:1||EphB3:1||Epidermal growth factor receptor:1||Epidermal growth factor receptor mutation:1||Epirubicin:1||Epithelialmesenchymal transition:1||Epithelialmesenchymal transition (EMT):1||EpsteinBarr virus:1||Esophageal squamous cell carcinoma:1||FGFR inhibitor:1||FGFR2b:1||FLUOROURACIL:1||FOLFOX:1||Far East:1||Febrile neutropenia:1||Firstline chemotherapy:1||GEJ cancer:1||GENEEXPRESSION:1||GLI1:1||GLI1:1||Gastric or gastroesophageal junction cancer:1||Gastroesophageal junction adenocarcinoma:1||Gemcitabine and carboplatin:1||Gli:1||Gli1:1||Glomus tumor:1||Granulocytic sarcoma:1||HEPATOCELLULARCARCINOMA:1||HIF:1||HIF1 alpha:1||Head and neck neoplasms:1||Hematologic malignancy:1||Heptaplatin:1||Hypoxiainducible factor1:1||II COLONCANCER:1||IL1 beta:1||Immunohistochemistry:1||Immunotherapy:1||Implantable venous access port:1||Infection:1||Inflammation:1||Inguinal hernia:1||Interventional procedures:1||Intravenous access:1||Iron chelator:1||Korea:1||Korean:1||Korean population:1||Korean red ginseng:1||LYVE1:1||Leucovorin:1||Longterm:1||Longterm efficacy:1||Lung adenocarcinoma:1||Lung disease:1||Lymph node staging:1||Lymphocytosis:1||MVAC protocol:1||MCL1 apoptosis regulator:1||MDAMB231:1||MDCT:1||MDM2:1||MEDIATED APOPTOSIS:1||MICROSATELLITEINSTABILITY:1||MOLECULARBIOLOGY:1||Macroautophagy:1||Marijuana extract:1||Matrix metalloproteinase (MMP)9:1||Metastatic breast cancer:1||Metastatic burden:1||Metastatic mucinous adenocarcinoma:1||Metastatic pancreatic adenocarcinoma:1||Metformin:1||Mitochondrial dysfunction:1||Mitogenactivated protein kinase (MAPK):1||Nend rule pathway:1||Nterminal arginylation:1||NFkappa B:1||NK/Tcell lymphoma:1||NOS3:1||NOXA:1||NSCLC:1||Napabucasin:1||Nasopharyngeal carcinoma:1||Neoplasm:1||Neoplasm invasiveness:1||Neuropathic pain:1||Nilotinib:1||Nonsmall cell lung carcinoma:1||Nonsmallcell lung cancer:1||Nonsmallcell lung carcinoma:1||Nuclear factor (NF)kappa B:1||Overall survival:1||PERKeIF2 alphaATF4CHOP SIGNALS:1||PI3K:1||PREDICT RECURRENCE:1||Paclitaxel:1||Pain management:1||Palliative:1||Pancreas neoplasm:1||Pancreatic adenocarcinoma:1||Parkin:1||Percutaneous drainage:1||Phosphatidylinositol:1||Phosphatidylinositol 3kinase (PI3K)/Akt:1||Phosphorylated signal transducer and activator of transcription 3:1||Placebo:1||Positronemission tomography:1||Postneoadjuvant chemotherapy pathological stage:1||Predictive:1||Preoperative chemotherapy:1||Primary tumor location:1||Prognostic:1||Prognostic factor:1||Prognostic factors:1||Prognostic model:1||Psoas muscles:1||RIP1:1||ROS:1||Radiation therapy:1||Radiological criteria:1||Recurrence:1||Reninangiotensin system:1||Resistance:1||Retrospective analysis:1||Review:1||S1:1||SQSTM1:1||SRC:1||STOMACHCANCER:1||SURGICAL ADJUVANT BREAST:1||Salvage therapy:1||Sarcoidosis:1||Second primary cancer:1||Secondline:1||Secondline chemotherapy:1||Sensitive:1||Sestrin 2:1||Shogaol:1||Signal pathway:1||Signal transducer and activator of transcription 3:1||Singleincision technique:1||Skeletalrelated event:1||Small cell lung cancer:1||Solid cancer:1||Sonic hedgehog:1||Sonic hedgehog (Shh):1||Splenic marginal zone lymphoma:1||Splenomegaly:1||Stage:1||Staphylococcus aureus:1||Stat3:1||Stem cells:1||Stents:1||Stomach:1||Strategy:1||Subcutaneous port:1||Systemic inflammatory markers:1||Tcell nonHodgkin lymphoma:1||TCGA:1||TGM2:1||THERAPY:1||TNFrelated apoptosisinducing ligand:1||TRAILINDUCED CASPASE8 ACTIVATION:1||TRAILINDUCED ER STRESS:1||TRAILResistance:1||TRAILresistance:1||TRANSCRIPTION FACTOR:1||Target therapy:1||Targeted therapy:1||Therapeutics:1||Trastuzumab:1||Treatment beyond progression:1||Tumor necrosis factor (TNF)related apoptosisinducing ligand (TRAIL):1||Tumorigenesis:1||Tyrosine kinase inhibitors:1||Tyrosine protein kinase inhibitors:1||Ubiquitination:1||University students:1||Ureter:1||Urinary tract obstruction:1||Urothelial carcinoma:1||Urothelial cell carcinoma:1||VEGF:1||VEGFD:1||Varicella zoster virus:1||Vascular endothelial growth factor:1||Vascular endothelial growth factor receptor2:1||Vertebral Osteomyelitis:1||Wild type:1||Xlinked inhibitor of apoptosis protein (XIAP):1||Young patients:1||adipokines:1||advanced gastric cancer:1||advanced non small cell lung cancer:1||autophagic cell death:1||autophagy:1||biliary tract carcinoma:1||body composition:1||bone morphogenetic protein:1||breast cancer:1||cFLIP:1||cJun Nterminal kinase:1||cJun Nterminal kinase (JNK):1||cJun NH2terminal kinase:1||cancer pain:1||cancer patients:1||cancer stem cell:1||cancer stem cells:1||cardiac glycoside:1||chemoradiotherapy:1||chemotherapy resistance:1||colorectal cancer (CRC):1||comorbidity:1||consensus molecular subtype:1||coronavirus disease 2019:1||death receptor 5:1||death receptors (DRs):1||digitoxin:1||docetaxel:1||docosahexaenoic acid:1||elderly:1||elderly patients:1||endoplasmic reticulum (ER) stress:1||epidermal growth factor receptor:1||epithelialtomesenchymal transformation:1||esophageal cancer:1||exercise:1||firstline therapy:1||fluoropyrimidine:1||fragile histidine triad (FHIT):1||gammaionizing radiation:1||gastrointestinal neoplasms:1||gemcitabine:1||genipin:1||glioma stem cells:1||haplotypes:1||hepatocellular carcinoma:1||hospice:1||human epidermal growth factor receptor 2:1||human immunodeficiency virus:1||iNOS:1||imatinib:1||immunohistochemisty:1||inflammation:1||influenza:1||interim 18FFDG PET:1||intradermal:1||invasion:1||irinotecan:1||kinase:1||korean red ginseng:1||liver metastasis:1||liverintestine cadherin:1||lung cancer:1||lymph node metastasis:1||mFOLFOX6:1||mFOLFOX6:1||macroH2A2:1||margetuximab:1||metastatic breast cancer:1||metastatic gastroesophageal adenocarcinoma:1||metformin:1||microsatellite instability:1||migration:1||mitomycin:1||more than thirdline:1||mucinous adenocarcinoma:1||noninferiority:1||nuclear respiratory factor 2 alpha subunit (Nrf2):1||opioid therapy:1||oral UFT:1||oral paclitaxel:1||oxaliplatin resistance:1||pSTAT3:1||paclitaxel:1||perception:1||phase 3:1||phloretin:1||phosphoinositide:1||phosphoinositide 3 kinase/Akt:1||platelet count:1||polypharmacological molecules:1||prognosis:1||prognosis factor:1||prognostic factors:1||prognostic model:1||programmed deathligand 1:1||progression free survival:1||propensity score:1||proteasome inhibitors:1||protein quality control:1||proteolysis:1||quality of life:1||questionnaire:1||radiation:1||randomized controlled trial:1||reactive oxygen species (ROS):1||refractory colon cancer:1||resectability:1||retifanlimab:1||runtrelated transcription factor 3:1||safety:1||sea cucumber (SC):1||secondline chemotherapy:1||secondline treatment:1||single nucleotide polymorphisms:1||sonic hedgehog:1||survival:1||target therapy:1||targeted therapy:1||taxane resistant:1||uPAR:1||ubiquitin:1||ubiquitin proteasome system:1||uracil plus tegafur (UFT):1||vascular endothelial growth factor:1||vascular endothelial growth factor A:1||vascular endothelial growth factor receptor2:1||volumetric parameter:1||생존:1||선별검사:1||수술 전 항암화학요법:1||암 환자:1||예후:1||요근:1||전이암:1||15LOX1:1||종양표지자:1||18FFDGPET/CT:1||3kinase (PI3K)/Akt:1||5FU:1||5Fluorouracil:1||ACEI/ARB:1||AF8c:1||ATTRACTION2:1||Acute myeloid leukemia:1||Adenocarcinoma:1||Adenoma:1||Aged:1||Albumin:1||Anthracycline:1||Apoptotic cell death:1||Autophagy:1||Axillary vein:1||BCL2 family member:1||BMP2:1||BONE MORPHOGENETIC PROTEIN2:1||Bax:1||Bcl2:1||Bcl2 protein family:1||BclxL:1||Bemarituzumab:1||Benefit predictors:1||Bicarbonate:1||Biliary tract cancer:1||Biliary tract cancers:1||Biomarker:1||Bone metastases:1||Bone morphogenesis protein2:1||Bone morphogenetic protein (BMP)2:1||Bone morphogenetic protein 2:1||Bone morphogenetic protein2:1||Bone morphogenetic protein2 (BMP2):1||Bone morphogenetic proteins:1||Brain:1||Breast neoplasms:1||Creactive protein:1||CARCINO:1||CBD:1||CCSC:1||CHEMOTHERAPY:1||CHOP:1||CLEAVAGE OF BAP31:1||CRC:1||CT:1||Caffeine:1||Cancer immune activity:1||Cancer patient:1||Cancer perception:1||Cancer stem cells:1||Cancerrelated fatigue:1||Capecitabine:1||Cetuximab Resistance:1||Chemotherapy, second line:1||Chest xray:1||Chronic myeloid leukemia:1||Cisplatin failure:1||Clinical stage:1||Clinical subtypes:1||Clinical trial:1||Codium extracts (CE):1||Colorectal canoe:1||Combination chemotherapy:1||Complication:1||Complications:1||Concomitant chemoradiation:1||Consensus subtype:1||Cyclopamine:1||DHP107:1||

STATISTICS: Total View :12,657,435; Today View :3,790

RSS_1.0 RSS_2.0 ATOM_1.0

73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265

Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.

Detailed Information

Keyword

BROWSE